Form 8-K - Current report:
SEC Accession No. 0000059478-25-000251
Filing Date
2025-10-30
Accepted
2025-10-30 07:03:41
Documents
15
Period of Report
2025-10-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lly-20251030.htm   iXBRL 8-K 49009
2 EX-99.1 q325lillysalesandearningsp.htm EX-99.1 218208
7 logoa31a.jpg GRAPHIC 14287
  Complete submission text file 0000059478-25-000251.txt   516049

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lly-20251030.xsd EX-101.SCH 4275
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT lly-20251030_def.xml EX-101.DEF 19144
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lly-20251030_lab.xml EX-101.LAB 36806
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lly-20251030_pre.xml EX-101.PRE 20303
17 EXTRACTED XBRL INSTANCE DOCUMENT lly-20251030_htm.xml XML 9814
Mailing Address LILLY CORPORATE CENTER DROP CODE 1094 INDIANAPOLIS IN 46285
Business Address LILLY CORPORATE CTR DROP CODE 1094 INDIANAPOLIS IN 46285 3172762000
ELI LILLY & Co (Filer) CIK: 0000059478 (see all company filings)

EIN.: 350470950 | State of Incorp.: IN | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-06351 | Film No.: 251432153
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)